循環器ジャーナル67巻4号

2019年10月発行

特集 冠動脈疾患のリスク管理のフロントライン Ⅰ．冠動脈疾患イベントリスクをどう評価する？

遺伝子解析でどう評価する？

著者： 加藤規弘¹

所属機関： ¹国立国際医療研究センター遺伝子診断治療開発研究部

ページ範囲：P.579 - P.584

Point
・冠動脈疾患では40%程度が遺伝要因に規定されると推測されている．
・GWASにより冠動脈疾患の遺伝子座が既に160近く見つかっている．
・遺伝的リスクスコアを用いて遺伝的な高リスク群の推定が可能となってきた．

参考文献

1) Nikpay M, Stewart AFR, McPherson R:Partitioning the heritability of coronary artery disease highlights the importance of immune-mediated processes and epigenetic sites associated with transcriptional activity. Cardiovasc Res 113:973-983, 2017

2) Musunuru K, Kathiresan S:Genetics of Common, Complex Coronary Artery Disease. Cell 177:132-145, 2019

3) 加藤規弘：ゲノムと循環器病．川名正敏，他（編）：カラー版循環器病学—アップデート版—．pp25-33，西村書店，2014

4) van der Harst P, Verweij N:Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease. Circ Res 122:433-443, 2018

5) Khera AV, Chaffin M, Aragam KG, et al:Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 50:1219-1224, 2018

6) Manolio TA, Collins FS, Cox NJ, et al:Finding the missing heritability of complex diseases. Nature 461:747-753, 2009

7) Kato N, Loh M, Takeuchi F, et al:Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nat Genet 47:1282-1293, 2015

8) Kato N, Takeuchi F, Tabara Y, et al:Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet 43:531-538, 2011

9) Khera AV, Emdin CA, Drake I, et al:Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med 375:2349-2358, 2016

10) Kilpeläinen TO, Bentley AR, Noordam R, et al:Multi-ancestry study of blood lipid levels identifies four loci interacting with physical activity. Nat Commun 10:376, 2019

11) Bentley AR, Sung YJ, Brown MR, et al:Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. Nat Genet 51:636-648, 2019

12) 加藤規弘：生活習慣病におけるゲノム医療とは．日本医師会雑誌147:1413-1417, 2018

13) Kullo IJ, Jouni H, Austin EE, et al:Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates:Effect on Low-Density Lipoprotein Cholesterol Levels（the MI-GENES Clinical Trial）. Circulation 133:1181-1188, 2016

14) Timpson NJ, Wade KH, Smith GD:Mendelian randomization:application to cardiovascular disease. Curr Hypertens Rep 14:29-37, 2012

15) Clarke R, Bennett DA, Parish S, et al:Homocysteine and coronary heart disease:meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med 9:e1001177, 2012

16) Cohen JC, Boerwinkle E, Mosley TH, Jr, et al:Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264-1272, 2006

17) Sabatine MS, Giugliano RP, Keech AC, et al:Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713-1722, 2017

18) Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al:Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79:514-523, 2006

-lowering alleles. Eur J Prev Cardiol 24:492-504, 2017